Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

37
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
37
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

41
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
41
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

22
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
22
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

19
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

20
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
20
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

27
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
27

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alterations in renal Na,K-ATPase activity and protein expression in rat models of pressure and volume overload.

Scientific reports·2025
Same author

Trandolapril Attenuates Pro-Arrhythmic Downregulation of Cx43 and Cx40 in Atria of Volume Overloaded Hypertensive and Normotensive Rats.

Biomolecules·2025
Same author

<i>Lacticaseibacillus rhamnosus</i> Probio-M9 Alters the Gut Microbiota and Mitigates Pulmonary Hypertension in a Rat Model.

Nutrients·2025
Same author

The Role of the Wnt/β-Catenin Pathway in the Modulation of Doxorubicin-Induced Cytotoxicity in Cardiac H9c2 Cells by Sulforaphane and Quercetin.

International journal of molecular sciences·2025
Same author

Brown adipose tissue: a potential therapeutic target for preventing cardiovascular disease in metabolic disorders.

Diabetology & metabolic syndrome·2025
Same author

Soluble Guanylate Cyclase Stimulator, BAY41-8543: A Promising Approach for the Treatment of Chronic Heart Failure Caused by Pressure and Volume Overload.

Pharmacology research & perspectives·2025

Related Experiment Video

Updated: Aug 22, 2025

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

17.4K

Does Myocardial Atrophy Represent Anti-Arrhythmic Phenotype?

Barbara Szeiffova Bacova1, Katarina Andelova1, Matus Sykora1

  • 1Centre of Experimental Medicine, Slovak Academy of Sciences, 84104 Bratislava, Slovakia.

Biomedicines
|November 11, 2022
PubMed
Summary

Cardiac atrophy, a decrease in heart muscle mass, can result from unloading. Understanding its mechanisms may lead to treatments preventing heart failure and arrhythmias.

Keywords:
arrhythmiascardiac unloadingconnexin43depressed contractilitymyocardial atrophy

More Related Videos

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

10.2K
Isolation of Atrial Myocytes from Adult Mice
08:34

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

10.6K

Related Experiment Videos

Last Updated: Aug 22, 2025

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

17.4K
Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

10.2K
Isolation of Atrial Myocytes from Adult Mice
08:34

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

10.6K

Area of Science:

  • Cardiology
  • Physiology

Background:

  • Cardiac atrophy, or myocardial atrophy, is a decrease in heart muscle mass.
  • It can be caused by mechanical or metabolic unloading from various conditions.
  • Cardiac deconditioning, characterized by reduced left ventricular mass, is a key feature.

Purpose of the Study:

  • To review the mechanisms underlying cardiac atrophy.
  • To discuss strategies for preventing, attenuating, or reversing myocardial atrophy.
  • To explore therapeutic targets for cardiac atrophy.

Main Methods:

  • Literature review of studies on cardiac atrophy.
  • Analysis of mechanisms, including molecular and cellular changes.
  • Discussion of potential interventions and therapeutic strategies.

Main Results:

  • Cardiac atrophy involves decreased left ventricular mass, potentially preventing arrhythmias.
  • Upregulation of connexin43 and enhanced PKCƐ signaling may contribute to an anti-arrhythmic phenotype.
  • Persistent atrophy can lead to cardiac dysfunction, heart failure, oxidative stress, inflammation, and fibrosis.

Conclusions:

  • Preventing or reversing myocardial atrophy may be a viable strategy for heart failure prevention.
  • Further research is needed to develop effective treatments for cardiac atrophy.
  • Improved awareness and identification of mechanisms are crucial for therapeutic development.